Article Text
Letters
Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis
Statistics from Altmetric.com
Footnotes
-
Contributors All the authors have given substantial contribution to: conception and design, or analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be published.
-
Competing interests ICMJE conflicts of interest for each author of this manuscript has been uploaded.
-
Ethics approval Provided by the Ethics committee of Rheumatism Foundation Hospital, Heinola, Finland.
-
Provenance and peer review Not commissioned; externally peer reviewed.